SRR10900558

—

b694395d-c3ec-5670-90ee-a0aefa786524

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type: —
cancer_type_detailed: —
subtype: —

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

OXIDATIVE_PHOSPHORYLATION+0.500
ADIPOGENESIS+0.300
FATTY_ACID_METABOLISM+0.200
PEROXISOME+0.200
PROTEIN_SECRETION+0.200
ANDROGEN_RESPONSE+0.100
BILE_ACID_METABOLISM+0.100
WNT_BETA_CATENIN_SIGNALING+0.100
ANGIOGENESIS+0.000
CHOLESTEROL_HOMEOSTASIS+0.000

Top 10 suppressed

APICAL_SURFACE-0.400
ALLOGRAFT_REJECTION-0.300
HEDGEHOG_SIGNALING-0.300
IL6_JAK_STAT3_SIGNALING-0.300
INTERFERON_ALPHA_RESPONSE-0.300
INTERFERON_GAMMA_RESPONSE-0.300
APICAL_JUNCTION-0.200
COMPLEMENT-0.200
EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
ESTROGEN_RESPONSE_EARLY-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#	Sample	Cancer type	Subtype	cos similarity
1	SJEPD031078_D2.RNA-Seq medullo-epn-umap@date-based	EPN	Posterior Fossa EPN	0.868
2	SRR12202452 bladder-landscape@3	—	—	0.840
3	877f3bcc-97ea-4b0e-9f61-98a9eaedd952 melanoma-umap@29	—	—	0.834
4	TCGA-DK-A6B1-01A-12R-A30C-07 bladder-landscape@3	—	—	0.804
5	MDT-AP-0395 medullo-epn-umap@date-based	Med	Medulloblastoma	0.802
6	SJEPD031010_D1.RNA-Seq medullo-epn-umap@date-based	EPN	EPN Tumor	0.799
7	BS_3F4FQJMR brain-umap@2	Supratentorial Ependymoma	—	0.798
8	SJEPD031319_D1.RNA-Seq medullo-epn-umap@date-based	EPN	EPN Tumor	0.796
9	BS_9NJHQE9F medullo-epn-umap@date-based	Med	Medulloblastoma	0.791
10	ULC1533T_S61 lung-landscapes@6	—	cohortA2	0.790

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 8 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)	tumor score	Best drug	reversal magnitude
OXIDATIVE_PHOSPHORYLATION	0.500	Remibrutinib	— uncovered
ADIPOGENESIS	0.300	Inavolisib	— uncovered
FATTY_ACID_METABOLISM	0.200	Inavolisib	— uncovered
PEROXISOME	0.200	Idelalisib	— uncovered
PROTEIN_SECRETION	0.200	Remibrutinib	— uncovered
ANDROGEN_RESPONSE	0.100	Inavolisib	— uncovered
BILE_ACID_METABOLISM	0.100	Inavolisib	— uncovered
WNT_BETA_CATENIN_SIGNALING	0.100	Inavolisib	— uncovered